Oncolytics Biotech Inc. Update Target $9.00
clinical trial capsules (Photo credit: Esthr) Sept.13 Oncolytics Biotech Inc. ONCY NYSE Investment recommendation Oncolytics provided an update on its Phase III clinical development of Reolysin in...
View ArticleOncolytics Biotech Inc. Q4 AND FULL YEAR 2012 RESULTS
Image via CrunchBase ONC : TSX : C$3.12 ONCY : NASDAQ BUY Target: C$8.00 COMPANY DESCRIPTION: Oncolytics Biotech is a biotechnology company with a biologic therapy in late stage development for the...
View ArticleOncolytics Biotech Inc. Risk/Reward
ONC: TSX : C$2.55 ONCY : NASDAQ BUY Target: C$8.00 COMPANY DESCRIPTION: Oncolytics Biotech is a biotechnology company with a biologic therapy in late stage development for the treatment of various...
View ArticleOncolytics Biotech Inc. MORE QUESTIONS THAN ANSWERS
ONC : TSX : C$2.00 ONCY : NASDAQ BUY Target: C$6.50 COMPANY DESCRIPTION: Oncolytics Biotech is a biotechnology company with a biologic therapy in late-stage development for the treatment of various...
View Article
More Pages to Explore .....